Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN versus ROBAXIN 750.
ROBAXIN vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant